Skip to main content

Table 3 Characteristics of the cluster with Behçet’s disease patients in MHLW registry

From: Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan

 

Total (n = 6754)

Cluster A (n = 1131)

Cluster B (n = 876)

Cluster C (n = 689)

Cluster D (n = 805)

Cluster E (n = 1369)

Cluster F (n = 799)

Cluster G (n = 1085)

P

Clinical symptoms used in clustering

 Oral ulcer, n (%)

6336 (93.8)

1050 (92.8)

867 (99.0)

361 (52.4)

805 (100.0)

1369 (100.0)

799 (100.0)

1085 (100.0)

< 0.001

 Skin involvement, n (%)

5483 (81.2)

493 (43.6)

755 (86.2)

177 (25.7)

805 (100.0)

1369 (100.0)

799 (100.0)

1085 (100.0)

< 0.001

 Eye involvement, n (%)

2344 (34.7)

87 (7.7)

115 (13.1)

538 (78.1)

805 (100.0)

0 (0.0)

799 (100.0)

0 (0.0)

< 0.001

 Genital ulcer, n (%)

4242 (62.8)

575 (50.8)

202 (23.1)

212 (30.8)

0 (0.0)

1369 (100.0)

799 (100.0)

1085 (100.0)

< 0.001

 Arthritis, n (%)

3311 (49.0)

461 (40.8)

484 (55.3)

192 (27.9)

390 (48.4)

1369 (100.0)

415 (51.9)

0 (0.0)

< 0.001

 Gastrointestinal involvement, n (%)

906 (13.4)

879 (77.7)

0 (0.0)

27 (3.9)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

< 0.001

 Vascular involvement, n (%)

148 (2.2)

0 (0.0)

121 (13.8)

27 (3.9)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

< 0.001

 Neurological involvement, n (%)

350 (5.2)

0 (0.0)

289 (33.0)

61 (8.9)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

< 0.001

Other characteristics

 Sex: female/male, n (%)

3990/2764 (59.1/40.9)

654/477 (57.8/42.2)

427/449 (48.7/51.3)

299/390 (43.4/56.6)

295/510 (36.6/63.4)

1032/337 (75.4/24.6)

479/320 (59.9/40.1)

804/281 (74.1/25.9)

< 0.001

 Age at onset (years, mean ± SD)

36.68 ± 14.23

39.91 ± 17.73

38.54 ± 14.46

38.78 ± 15.14

36.82 ± 13.09

35.58 ± 12.64

34.45 ± 12.00

33.38 ± 12.37

< 0.001

 Observation period (years, mean ± SD)*

4.14 ± 7.62

4.05 ± 7.71

4.18 ± 7.28

6.32 ± 9.95

3.82 ± 6.91

3.07 ± 6.06

6.19 ± 9.90

2.87 ± 5.57

< 0.001

 Pathergy test, n/available data number (%)

1361/4225 (32.2)

225/706 (31.9)

171/536 (31.9)

117/431 (27.1)

149/404 (29.6)

295/860 (34.3)

175/508 (34.4)

229/680 (33.7)

0.099

 HLA-B51, n/available data number (%)

1389/3141 (44.2)

172/513 (33.5)

237/492 (48.0)

172/358 (48.0)

221/413 (53.5)

244/599 (40.7)

164/321 (51.1)

179/443 (40.4)

< 0.001

 Fulfilling ISG criteria, n (%)

4980 (73.7)

405 (35.8)

333 (38.0)

185 (26.9)

805 (100.0)

1368 (99.9)

799 (100.0)

1085 (100.0)

< 0.001

 Fulfilling ITR-ICBD criteria, n (%)

5586 (82.7)

657 (58.1)

456 (52.1)

416 (60.4)

805 (100.0)

1368 (99.9)

799 (100.0)

1085 (100.0)

< 0.001

 Recent hospitalization, n/available data number (%)**

1556/6002 (25.9)

400/971 (41.2)

299/771 (38.8)

144/625 (23.0)

77/738 (10.4)

271/1195 (22.7)

121/728 (16.6)

244/974 (25.1)

< 0.001

  1. ISG International Study Group, ITR-ICBD International Team for the Revision of the International Criteria for Behçet’s Disease
  2. *“Observation period” indicates the period from disease onset to application of specific disease by the Japanese government
  3. **“Recent hospitalization” indicates episode of admission less than 6 months per patients